EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Vaccination in Multiple Myeloma: Challenges and Strategies

Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Santino Caserta, Francesco Mendicino, Fortunato Morabito, Massimo Gentile

European Journal of Haematology · 2025-10 · 115 (4) · 334-343

DOI: 10.1111/ejh.70013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 26.07.2025. Verfasst von Enrica Antonia Martino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, Cosenza, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Vaccination. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple myeloma (MM) is a hematological malignancy characterized by profound immunosuppression resulting from both disease‐related mechanisms and treatment‐induced immune dysfunction. This compromised immune status markedly increases susceptibility to infections, a leading cause of morbidity and mortality in MM patients. While vaccination represents a cornerstone of infection prevention, standard immunization strategies often yield suboptimal responses in this population.

Objectives

This review synthesizes current evidence on the immunological barriers and clinical effectiveness of vaccination in MM. We evaluate vaccines targeting influenza, Streptococcus pneumoniae , SARS‐CoV‐2, and other relevant pathogens, and explore determinants influencing vaccine efficacy, including optimal timing, formulation, and patient‐specific immune parameters.

Methods

A comprehensive literature review was conducted, encompassing clinical trials, retrospective cohort studies, expert consensus guidelines, and population‐based data. Extracted outcomes included serological responses, infection‐related events, and vaccine safety in MM patients.

Results

Patients with MM exhibit impaired vaccine responses due to hypogammaglobulinemia, T‐ and B‐cell dysfunction, and therapy‐induced lymphodepletion. Despite modest immunogenicity, influenza and pneumococcal vaccines reduce respiratory infections and hospitalizations. Sequential administration of PCV13 followed by PPSV23, as well as post‐autologous stem cell transplantation (ASCT) three‐dose regimens, is associated with reduced pneumonia incidence. COVID‐19 vaccines elicit variable responses, particularly in patients on anti‐CD38 or BCMA‐targeted therapies, highlighting the need for booster doses and, in selected cases, prophylactic monoclonal antibodies. Vaccines against herpes zoster, hepatitis B, and Haemophilus influenzae type B are also recommended, particularly around ASCT. Immunophenotypic markers such as CD19+ B‐cell and CD4+ T‐cell counts are predictive of vaccine responsiveness, supporting immune profiling as a tool for individualized vaccination planning.

Conclusions

Vaccination remains a critical component of infection prevention in MM. Although immunogenicity may be attenuated, clinical benefits—namely, reduced infection burden and healthcare utilization—support broad vaccine implementation. A personalized approach, considering the treatment phase, disease control, and immune status, is essential to optimize vaccine effectiveness. Ongoing research into high‐dose, adjuvanted, and next‐generation vaccines is critical to enhance protection in this vulnerable population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaVaccinationHumansCOVID-19SARS-CoV-2COVID-19 VaccinesPneumococcal VaccinesInfluenza Vaccines

Stichwörter der Autor:innen

MMimmunosuppressionvaccination

Substanzen

COVID-19 VaccinesPneumococcal VaccinesInfluenza Vaccines

Autor:innen und Institutionen

  • Hematology Unit, Department of Onco-Hematology, Cosenza, Italy.
  • Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
  • AIL Sezione di Cosenza, Cosenza, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

Zitieren

APA

Martino, E. A., Vigna, E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Caserta, S., Mendicino, F., Morabito, F., & Gentile, M. (2025). Vaccination in Multiple Myeloma: Challenges and Strategies. European Journal of Haematology, 115(4), 334-343. https://doi.org/10.1111/ejh.70013

Vancouver

Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, et al. Vaccination in Multiple Myeloma: Challenges and Strategies. European Journal of Haematology. 2025;115(4):334-343. doi:10.1111/ejh.70013

BibTeX
@article{Martino2025,
  author = {Martino, Enrica Antonia and Vigna, Ernesto and Bruzzese, Antonella and Amodio, Nicola and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Caserta, Santino and Mendicino, Francesco and Morabito, Fortunato and Gentile, Massimo},
  title = {Vaccination in Multiple Myeloma: Challenges and Strategies},
  journal = {European Journal of Haematology},
  year = {2025},
  volume = {115},
  number = {4},
  pages = {334--343},
  doi = {10.1111/ejh.70013}
}
Kostenlos starten →